semaglutide and ischemic colitis Semaglutide-Associated in a Patient Without Traditional Risk Factors: A Case Report Can Semaglutide Cause Colitis? Evidence

Semaglutide, a GLP-1 receptor agonist used for type 2 diabetes and weight management, primarily loses potency after expiration rather than becoming toxic

Reduces Muscle Damage : L-Carnitine may lower markers of muscle stress, complementing its role in recovery for active individuals

Why is real-world effectiveness important for GLP-1 programs

Real-World Results For GLP-1 Drugs Underwhelm, Study Says WEDNESDAY, June 11, 2025 (HealthDay News) Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound arent as impressive as those promised by the drugs clinical trials, a new study says.People taking such GLP-1 drugs lost just under 9% of their body weight on average after a year, researchers reported June 10 in the journal Obesity.Thats far less than the 15% to 21% body weight reduction promised by the clinical trials that led to the approval of Wegovy (semaglutide) and Zepbound (tirzepatide) for weight loss, researchers said.Patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trial, lead investigator Hamlet Gasoyan said in a news release

Start your morning